Flerie's portfolio company Xintela moves osteoarthritis programme into new subsidiary and aims for early commercialisation

Flerie AB's (publ) portfolio company Xintela has announced that it will transfer its osteoarthritis programme, based on the stem cell product XSTEM, to a new subsidiary with dedicated management. Xintela aims to begin commercialisation in selected markets by the end of 2027, while continuing clinical development. Flerie, Xintela's principal shareholder, supports the strategy.

"XSTEM has delivered very strong results in knee osteoarthritis. Placed in its own company with focused management, the programme is better positioned to attract capital and partners. This is a good example of how Flerie's ownership model, combining scientific and financial expertise, can contribute to value creation," says Arvid Söderhäll, Venture Partner at Flerie.

Flerie's wholly owned subsidiary Flerie Invest AB has provided Xintela with an interest-free, secured credit facility of up to SEK 10 million to support ongoing operations as the strategy is implemented. The facility is available for drawdown until 30 March 2027.

Read Xintela's full press release here: https://xintela.se/en/mfn_news/xintela-sharpens-osteoarthritis-focus-with-revised-xstem-development-and-commercialisation-strategy/

Flerie's holding in Xintela amounts to 60%.

For more information:
Arvid Söderhäll, Venture Partner
Email: ir@flerie.com

About the stem cell product XSTEM®
XSTEM® is an allogeneic stem cell product based on integrin #10#1-selected mesenchymal stem cells. The cells are intended for local administration to damaged tissue and are being developed to support the body's own repair processes. Xintela's selection platform aims to identify a homogeneous cell population with consistent properties, which is key to further clinical development and reproducible manufacturing.

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

Flerie's portfolio company Xintela moves osteoarthritis programme into new subsidiary and aims for early commercialisation